← BrightSpring Health Services, Inc. Common Stock overview

BrightSpring Health Services, Inc. Common Stock vs AMN Healthcare Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

August 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Latest
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

AMN Healthcare Services Inc (AMN)

Q3 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

August 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

Latest
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

© 2026 MarketIVWhy